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Transcription factors that mediate
epithelial–mesenchymal transition lead to multidrug
resistance by upregulating ABC transporters
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Development of multidrug resistance (MDR) is a major deterrent in the effective treatment of metastatic cancers by
chemotherapy. Even though MDR and cancer invasiveness have been correlated, the molecular basis of this link remains
obscure. We show here that treatment with chemotherapeutic drugs increases the expression of several ATP binding cassette
transporters (ABC transporters) associated with MDR, as well as epithelial–mesenchymal transition (EMT) markers, selectively
in invasive breast cancer cells, but not in immortalized or non-invasive cells. Interestingly, the mere induction of an EMT in
immortalized and non-invasive cell lines increased their expression of ABC transporters, migration, invasion, and drug
resistance. Conversely, reversal of EMT in invasive cells by downregulating EMT-inducing transcription factors reduced their
expression of ABC transporters, invasion, and rendered them more chemosensitive. Mechanistically, we demonstrate that the
promoters of ABC transporters carry several binding sites for EMT-inducing transcription factors, and overexpression of Twist,
Snail, and FOXC2 increases the promoter activity of ABC transporters. Furthermore, chromatin immunoprecipitation studies
revealed that Twist binds directly to the E-box elements of ABC transporters. Thus, our study identiﬁes EMT inducers as novel
regulators of ABC transporters, thereby providing molecular insights into the long-standing association between invasiveness
and MDR. Targeting EMT transcription factors could hence serve as novel strategies to curb both metastasis and the associated
drug resistance.
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The highly orchestrated molecular circuitries that ensure
normal functioning of each cell are disrupted in cancer,
making it a disease of uncontrolled cell proliferation. Although
decades of research have gone into understanding the
causes and mechanisms of cancer, yet relatively little
progress has been made to effectively cure this disease.
The development of therapies to cure cancer is further
complicated by the emergence of drug resistance. For an
effective treatment of cancers, conventional chemotherapy
employsthe useofa combinationof drugs.
1However, instead
of succumbing, cancer cells often remain refractory to
chemotherapeutic drugs owing to the development of drug
resistance.
Cancers can either be inherently drug resistant before drug
exposure or can acquire drug resistance after the adminis-
tration of drugs.
2 Those that respond to chemotherapy at the
start of the treatment can often simultaneously become
resistant to different classes of drugs resulting in multidrug
resistance (MDR).
2 Development of MDR is also the leading
cause of cancer recurrence, with the resultant cancers
behaving more aggressive than at the start of treatment.
Several adaptive mechanisms contribute to drug resistance,
including activation of DNA repair pathways, alteration of
drugtargets,decreaseduptakeofchemotherapeuticdrugs,
2,3
and most signiﬁcantly, an increased active efﬂux of drugs
mediated by transporters belonging to the ATP binding
cassette (ABC transporters) superfamily of proteins.
4
ABC transporters form the largest transportome in the
human genome.
4 They are ubiquitously and heterogeneously
expressed in various body tissues and important pharmaco-
logical barriers where they have a pivotal role in host cell
detoxiﬁcation and protection of the body against xenobio-
tics.
1,2 ABC transporters are also overexpressed in several
cancers.
1,2Thesetransportersactivelyefﬂuxawidespectrum
of commonly employed chemotherapeutic drugs like estra-
mustine, mitoxantrone, anthracyclines, vinca alkaloids,
taxanes, thiopurines, and so on.
5 Recently, as many as
16 ABC transporters have been implicated in MDR.
5 There-
fore, understanding the mechanisms that regulate ABC
transporter expression becomes imperative in addressing
the problem of MDR.
Increased ABC transporter expression has been correlated
with aggressive and invasive cancers, which also tend to
be more chemoresistant.
5–7 One of the early steps in the
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www.nature.com/cddisinvasion-metastasis cascade includes epithelial–mesen-
chymal transition (EMT) through which polarized epithelial
cells undergo major phenotypic changes and acquire a more
mesenchymal morphology.
8–10 EMT can be triggered by a
myriad of stimuli,
9 several of which ultimately culminate in the
overexpression of transcription factors like Snail, Twist, Slug,
and so on.
10 Overexpression of some of these transcription
factors has also been associated with chemoresistance,
although their depletion has been shown to increase
drug sensitivity.
11–13 Even though these studies establish a
strong correlation between EMT and drug resistance, a clear
understanding of the molecular basis for the association
between invasion and drug resistance is still lacking.
In this study, we have investigated the role of EMT-inducing
transcription factors in drug resistance mediated by ABC
transporters in breast cancer cells. We demonstrate that the
very transcription factors that lead to EMT and invasion also
orchestrate the overexpression of drug transporters by
directly modulating their promoter activity, thus providing a
novel molecular mechanism for the long-standing association
between invasiveness and drug resistance.
Results
Heterogeneous expression of ABC transporters in
breast cells. To assess the basal level of expression
of the 16 ABC transporters implicated in drug resistance,
5
we undertook a detailed reverse transcriptase polymerase
chain reaction (RT-PCR)-based analysis in nine breast
epithelial cell lines comprising of immortalized, non-invasive
and invasive cell types for our study. We found a large
heterogeneity in the number and level of expression of ABC
transporters, but not a signiﬁcant difference across cell
types (Figure 1a and Supplementary Table S1 and Figure
S1A). Expression analysis at the protein level for three
ABC transporters, viz, ABCB1, ABCC1, and ABCG2, also
revealed a similar heterogeneity (Supplementary Figure
S1B). To assess if a similar heterogeneity exists in vivo,
we analyzed primary tissues from untreated normal, ductal
carcinoma in situ (DCIS), and invasive ductal carcinoma
(IDC) patient samples. Among the primary samples also,
heterogeneity in both number and level of expression of ABC
transporters was observed (Figure 1b and Supplementary
Figure S1C). In addition, the DCIS and the IDC samples
expressed a higher number of ABC transporters in
comparison to the normal tissue (Figure 1b and Supple-
mentary Figure S1C), suggesting that the process of tumor
progression in vivo may lead to the upregulation of ABC
transporter expression.
Effect of chemotherapeutic drug treatment on ABC
transporter expression. Previous studies have shown an
increase in drug resistance phenotype on chemotherapeutic
drug treatment.
2 To understand the effect of
chemotherapeutic treatment on the expression of ABC
transporters, we exposed the panel of immortalized,
non-invasive and invasive cells to an 1-week treatment with
doxorubicin (Dox), a commonly used chemotherapeutic drug
in breast cancer treatment regimens, and examined their
expression of 16 ABC transporters.
5 The time of treatment
and the concentration of drug used were determined based
on time-course analyses and 3-(4, 5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) cytotoxicity assays,
respectively, as detailed in Materials and Methods.
Dox treatment of two immortalized cell lines, MCF10A
(Figure 2b) and HBL100 (Supplementary Figure S2A), did not
signiﬁcantly alter the expression of any of the 16 ABC
transporters. Dox treatment of the two non-invasive cell
types, MCF7 and T47D, led to an increase in only one ABC
transporter in each cell line, viz, ABCB11 in MCF7 (Figure 2b)
and ABCC5 in T47D (Supplementary Figure S2A) cells.
Interestingly, Dox treatment of the invasive cell types,
MDAMB231 (Figure 2b) and MDAMB435 (Supplementary
Figure S2A), led to a signiﬁcant increase in as many as 7–9
ABC transporters. To assess if this effect was speciﬁc to
Dox, we treated MCF10A, MCF7 and MDAMB231 cells with
yet another drug, mitoxantrone. Although no change was
observed in either MCF10A or MCF7 cells, a signiﬁcant
increase in as many as six ABC transporters was observed in
MDAMB231 cells (Supplementary Figure S2B).
To assess the behavior of primary samples, cells derived
from patient biopsies were treated with Dox for a week in
culture (Figure 2c) and then assessed for ABC transporter
expression. Although an appreciable increase in ABC
transporters was not observed in Dox-treated primary normal
breast cells, many ABC transporters were upregulated in
the Dox-treated primary breast cancer cells (Figure 2d and
Supplementary Figure S2C). To further assess if these in vitro
drug treatments mimicked in vivo behavior, we undertook
the expression analysis of ABC transporters in several
chemotherapy-treated primary patient samples. In concor-
dance with previous reports,
1 our results revealed that
chemotherapeutic treatment signiﬁcantly upregulated the
expression of many ABC transporters in the cancer samples
(Figure 2e and Supplementary Figure S2D).
Takentogether,ourdatademonstratedthatthepresenceof
chemotherapeutic drugs causes an increased expression of
ABC transporters only in invasive breast cancer cells,
revealingastrongcorrelationbetweentheinvasivephenotype
and ABC transporter-mediated drug resistance phenotype.
These data further suggested that the cellular machinery
required to orchestrate the upregulation of ABC transporters
in response to drug treatment is inherent within the invasive
cells.
Effect of chemotherapeutic drug treatment on EMT and
invasion. Recent studies have suggested a correlation
between EMT and chemoresistance.
14 To assess if 1-week
Dox treatment has an effect on EMT in our system, we
undertook RT-PCR and western blot analysis of several
markers of EMT. Upon Dox treatment, no signiﬁcant change
in EMT markers was observed in immortalized (MCF10A)
and non-invasive (MCF7) cell lines; however, a signiﬁcant
increase was observed in the invasive cell line (MDAMB231)
(Figures 3a and b). Similar results were obtained for another
set of immortalized (HBL100), non-invasive (T47D) and
invasive (MDAMB435) cell lines (Supplementary Figure
S3A). This was also accompanied with the acquisition
of a more mesenchymal phenotype in the invasive cells
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Cell Death and Disease(Figure 2a). Another hallmark feature of EMT is an increase
in the migratory capability of cells.
8 In comparison to the
untreated cells, a previous treatment with Dox for 72h
caused a threefold increase in motility in MDAMB231 cells
(Figures 3c and d) and a twofold increase in motility in
MDAMB435 cells (Supplementary Figure S3B) in wound
healing assays. To test whether Dox treatment can also
cause an increase in the invasive properties of MDAMB231
cells, we undertook an RT-PCR-based analysis of several
matrix metalloproteinase (MMP) markers that are known to
be overexpressed during metastasis of cancer cells. A
signiﬁcant increase in the expression of several MMPs
(MMP1, MMP2, MMP3 and MMP13) was observed on Dox
treatment (Figure 3e). To further validate this, a functional
in vitro assay of invasion through Matrigel was undertaken.
As seen in Figure 3f, Dox treatment signiﬁcantly increased
the invasive potential of only MDAMB231 cells and not that of
MCF10A or MCF7 cells. Collectively these results showed
that drug treatment further potentiates the migratory and
invasive potential of invasive breast cancer cell lines.
MCF10A MCF7 MDAMB231
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Figure 1 Breastepithelialcellshaveaheterogeneousexpressionof ABCtransporters.(a)RepresentativegraphsshowingrelativemRNAexpressionofABCtransporters
in immortalized (MCF10A and HBL100), non-invasive (MCF7 and T47D), and invasive (MDAMB231 and MDAMB435) breast epithelial cell lines as analyzed by RT-PCR,
n¼3. (b) Representative graphs showing relative mRNA expression of ABC transporters in primary normal (NB), DCIS, and IDC breast samples as analyzed by RT-PCR.
n¼3 for NB, n¼6 for DCIS, and n¼3 for IDC samples
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Cell Death and DiseaseEffect of EMT induction on ABC transporter
expression. As our earlier results demonstrated that drug
treatment leads to an increase in the expression of both ABC
transporters and the invasive phenotype in only invasive
cells, we hypothesized that the molecular mechanisms that
regulate EMT and invasiveness could also co-regulate ABC
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Cell Death and Diseasetransporter expression. To test this, we asked if induction
of EMT in a non-invasive cell line will elicit an increase in
ABC transporter expression. To address this, we induced
EMT in non-invasive MCF7 cells by TGFb treatment.
9 One
week of TGFb treatment led to a signiﬁcant increase in the
levels of TGFBIp, a read out of TGFb signaling (Figure 4a),
and a signiﬁcant increase in levels of several mesenchymal
markers (Figure 4a), indicative of EMT induction. A
Figure 2 Dox treatment upregulates ABC transporter expression only in invasive cells. (a) Phase-contrast microscopic images taken after 1 week of untreated (UT) and
doxorubicin-treated (Dox) MCF10A, MCF7, and MDAMB231 breast epithelial cell lines. Scale bar¼100mm. (b) Graphs represent relative mRNA expression of 16 ABC
transporters after 1-week Dox treatment in MCF10A, MCF7, and MDAMB231 breast epithelial cell lines, n¼3. Statistical signiﬁcance for all the experiments was determined
using ratio t-test. Error bars denote ±S.E.M. *Po0.05; **Po0.01; ***Po0.001. The insets represent immunoblot analysis of whole-cell lysates for the expression of three
ABC transporters, viz, ABCB1, ABCC1, and ABCG2 in the absence or presence of Dox. (c) Phase-contrast microscopic images of primary breast tissue-derived cells in the
presence(Dox)orabsence(UT)ofDoxfor7days;scalebar¼100mm.(d)RepresentativegraphshowingrelativemRNAexpressionof16ABCtransportersafter1-weekDox
treatment in primary normal- and tumor-derived breast epithelial cells, n¼4. (e) Representative graph showing relative mRNA expression of ABC transporters in
chemotherapy-treated patient-derived primary normal (CT-NB) and tumor (CT-CB) breast samples. n¼2 for normal and n¼3 for tumor samples
UT
Dox
G
e
n
e
 
e
x
p
r
e
s
s
i
o
n
 
n
o
r
m
a
l
i
z
e
d
t
o
 
H
P
R
T
 
MDAMB231
Dox
G
e
n
e
 
e
x
p
r
e
s
s
i
o
n
 
n
o
r
m
a
l
i
z
e
d
t
o
 
H
P
R
T
 
UT
Dox
MCF10A
G
e
n
e
 
e
x
p
r
e
s
s
i
o
n
 
n
o
r
m
a
l
i
z
e
d
t
o
 
H
P
R
T
 
UT MCF7
UT  Dox 
24h
0h
D
i
s
t
a
n
c
e
 
m
i
g
r
a
t
e
d
 
(

m
)
150
200
100
50
0
Vim
Zeb1
α-tubulin
N-cad
Twist
Dox
MCF10A MCF7  MDAMB231 
15
20
10
5
0
25
G
e
n
e
 
e
x
p
r
e
s
s
i
o
n
 
n
o
r
m
a
l
i
z
e
d
t
o
 
H
P
R
T
I
n
v
a
s
i
o
n
 
i
n
d
e
x
6
4
2
0
8
5
3
1
7
+ - + - + -
20
15
10
5
0
50
40
30
0
20
10
0.0
0.2
0.4
0.6
0.8
1.0
5
10
15
20
40
60
80
100
Figure 3 Dox treatment of invasive cells leads to the upregulation of EMT markers and invasiveness. (a) Graphs represent relative mRNA expression of EMT markers
after1-weekDoxtreatmentinMCF10A,MCF7,andMDAMB231cells,n¼3.Errorbarsdenote±S.E.M.*Po0.05.(b)Immunoblotanalysisofwhole-celllysatesofMCF10A,
MCF7, and MDAMB231 cells for the expression of EMT markers in the absence or presence of Dox. (c) Photomicrographs represent cell migration of untreated (UT) or
doxorubicin-treated (Dox) MDAMB231cells in wound healing assay at 0 and 24h. Scale bar¼500mm. (d) Graph represents distance migrated by cells in the experiment (c)
calculated as a difference of distance between the two edges of the wounds at 0 and 24h measured in mm using the ProgRes capture software, n¼8. Error bars denote
±S.E.M.**Po0.01. (e) Graph representsrelativemRNAexpressionof MMP markers after1 week of Dox treatment in MDAMB231cells, n¼3. Error bars denote±S.E.M.
*Po0.05; **Po0.01. (f) Graph represents invasion index calculated as ratio of percentage cell invasion of Dox-treated cells and -untreated control cells through Matrigeli n
Boyden chamber assay; n¼2 for MCF10A and MCF7, and n¼3 for MDAMB231. Error bars denote ±S.E.M. *Po0.05
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Cell Death and Diseasesubsequent analysis of ABC transporters in these cells
revealed a signiﬁcant increase in the levels of ﬁve ABC
transporters compared with untreated controls (Figure 4b).
To further strengthen our hypothesis that EMT regulates
ABC transporter-mediated drug resistance, we chose to
induce EMT in MCF7 cells by a second approach involving
the overexpression of EMT-inducing transcription factors.
MCF7 cells were transiently transfected with Twist
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Cell Death and Diseaseexpressing vector. An RT-PCR analysis after 48h of
transfection conﬁrmed the overexpression of Twist, and the
upregulation of various mesenchymal markers, thereby
conﬁrming the induction of EMT (Figure 4c). Further, we
observed that the mere overexpression of Twist led to a
concomitant upregulation of several of the 16 ABC
transporters (Figure 4d). Similar results were obtained with
transient transfections of other EMT-inducing transcription
factors such as Snail (Supplementary Figures S4A and B)
and FOXC2 (Supplementary Figures S4C and D).
To address if this upregulation of ABC transporters in
response to EMT induction is restricted to non-invasive
cancer cells, we tested yet another cell type, viz, immortalized
humanmammaryepithelial cells(HMLE).
15HMLE cellsstably
overexpressing Twist (HMLE-Twist) were generated by
retroviral transduction. These cells showed a mesenchymal
morphology, increased migration and invasion, upregulation
of various EMT markers, and downregulation of E-cadherin
(Figures 4e–h). Concomitantly, we observed an increase in
the levels of ﬁve ABC transporters (Figure 4i). Similar results
were obtained with HMLE cells transduced with Snail- and
FOXC2-expressing retroviruses (Supplementary Figures
S4E–I). In addition, HMLE cells stably overexpressing Twist,
FOXC2, or Snail tolerated a 10-fold higher Dox concentration
in comparison with the uninfected control HMLE cells, as
assessed by an MTT cytotoxicity assay (Figure 4j). Further-
more, similar to invasive cell types, HMLE-Twist cells showed
further upregulation of several ABC transporters on treatment
with Dox (Figure 4k). Thus, an immortalized cell line that
otherwise is sensitive to chemotherapeutic drugs can be
rendered drug resistant by the mere introduction of EMT-
inducing transcription factors. Taken together, these results
clearly demonstrated that EMT induction simultaneously
upregulated the expression of several ABC transporters in
non-invasive cancer and immortalized cell lines.
Reversal of EMT leads to increased drug sensitivity. To
further test the speciﬁcity of the link between EMT and ABC
transporter expression, we analyzed the effect of
downregulating EMT-inducing transcription factors using
the RNAi approach. We found that transfection of invasive
MDAMB231 cells with siRNA oligos targeting Twist (Twist
siRNA) or Zeb1 (Zeb1 siRNA) led to a reversal of the EMT
phenotype, as judged by the emergence of epithelial looking
colonies (Figure 5a), upregulation of E-cadherin, as well as
reduction in the levels of several EMT markers (Figure 5b).
Twist and Zeb1 siRNA also prevented Dox-mediated
upregulation of EMT-inducing transcription factors like
Snail, Slug, FOXC2, and Zeb2 (Figure 5b). Further, both
Twist (Figure 5c and Supplementary Figure S5) and Zeb1
siRNA (Figure 5c) decreased the basal levels of ABC
transporters in MDAMB231 cells. In addition, Twist and
Zeb1 siRNA signiﬁcantly prevented the Dox-mediated
induction of several ABC transporters compared with
control siRNA transfections (Figure 5c). Twist and Zeb1
knockdown also reduced their chemoresistance (Figure 5d).
Furthermore, on Twist knockdown, MDAMB231 cells failed to
show Dox-mediated increase in invasion (Figure 5e). Thus,
these set of experiments conﬁrmed that the upregulation of
ABC transporters increase in migration, invasion, and
chemoresistance in response to Dox treatment, via, EMT-
inducing transcription factors.
EMT transcription factors directly modulate ABC
transporter expression. Snail, Twist, and FOXC2 have
been implicated as transcriptional activators for genes like
CDK inhibitor p15
INK4b, Akt2 and plasminogen activator
inhibitor type I, respectively.
16–19 To assess whether these
EMT factors could act as transcriptional activators for ABC
transporters as well, we undertook a promoter–reporter
assay for ABCC5. MCF7 cells were co-transfected with
constructs encoding for ABCC5-Luc along with one of the
following vectors: pBp-empty vector, pBp-Snail, pBp-mTwist,
or pBp-FOXC2. Our results demonstrated that all the three
EMT-inducing transcription factors, Snail, Twist, and FOXC2,
were able to signiﬁcantly increase the promoter activity of
ABCC5 in comparison to the pBp-empty vector control
(Figure 6a).
Further, a bioinformatic-based analysis of the promoter
regions of the 16 ABC transporters revealed the presence of
several binding sites for EMT-inducing transcription factors
like Snail, Slug, Twist (E-boxes), FOXC2 (forkhead domains),
E12, and E47 (Table 1). To assess whether the EMT-inducing
transcription factors can directly bind to the consensus
binding elements present in the promoters of ABC transpor-
ters (Figure 6b), we undertook a chromatin immunoprecipita-
tion (ChIP) assay with MCF7 cells transiently transfected with
pCDNA3-Flag-Twist construct. The ChIP assay revealed that
Flag-Twist indeed binds speciﬁcally to E-boxes present in the
promoter region of ABCC4 and ABCC5 genes (Figure 6c).
Taken together, these results revealed that EMT-inducing
transcription factors can directly bind to the promoters of ABC
transporters and thus regulate their expression.
Discussion
Cancer invasiveness has long been associated with
increased drug resistance; yet, little is known about the
Figure 4 EMTinductionupregulatesABCtransporterexpression.GraphsrepresentrelativemRNAexpressionofEMTmarkers(a)andABCtransporters(b)after1-week
treatment of MCF7 cells with TGFb, n¼4. Error bars denote ±S.E.M. *Po0.05; **Po0.01. Graphs represent relative mRNA expression of EMT markers (c) and ABC
transporters (d) in MCF7 cells transiently overexpressing mTwist, n¼4. Error bars denote ±S.E.M. *Po0.05; **Po0.01. (e) Phase-contrast images of parent HMLE cells
andHMLEcellsstablyoverexpressingmTwist(HMLE-mTwist); scalebar¼100mm. (f)Graphrepresentsdistance migratedbycellsin woundmigrationassaycalculatedas a
differenceofdistancebetweenthetwoedgesofthewoundsat0and24hmeasuredinmmusingtheProgRescapturesoftware,n¼4.Errorbarsdenote±S.E.M.**Po0.01.
(g) Graph represents cell invasion in arbitrary units (AU) calculated as a ratio of cells invaded through Matrigel to the total number of cells plated, n¼3. Error bars denote
±S.E.M.**Po0.01.GraphsrepresentrelativemRNAexpressionofEMTmarkers(h)andABCtransporters(i)inHMLEcellsstablyoverexpressingmTwist,n¼3.Errorbars
denote ±S.E.M. *Po0.05. (j) Dose–response curves of parent HMLE cells versus HMLE cells stably expressing mTwist/FOXC2/Snail treated with doxorubicin for 48h. The
dotted lines represent the IC50 values. (k) Graph represents relative mRNA expression of 16 ABC transporters in HMLE-mTwist cells after 1 week of Dox treatment, n¼3.
Error bars denote ±S.E.M. *Po0.05; **Po0.01; ***Po0.001
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Cell Death and Diseasemolecular mechanisms linking the two phenomena. We
show here that the transcription factors that mediate EMT,
a process intricately associated with cancer invasion-
metastasis cascade, also regulate the expression of ABC
family of drug transporters that mediate MDR.
Heterogeneous expression of ABC transporters by
cancer cells. Several studies have identiﬁed ABC trans-
porters as important players in cancer chemoresistance
5
leading to the development of anticancer strategies based on
targeting these transporters.
1 Despite addressing the toxicity
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Figure 5 Reversal of EMT leads to increased drug sensitivity. (a) Photomicrographs of MDAMB231 cells transfected with control, Twist, or Zeb1 siRNA in the presence
and absence of Dox treatment for 72h. Scale bar¼100mm. Gel pictures depict RT-PCR analysis of EMT markers (b) and ABC transporters (c) in MDAMB231 cells
transfectedwith control,Twist,orZeb1siRNAinthepresence andabsenceofDox treatmentfor 72h.(d)Dose–responsecurvesofMDAMB231cellstransfectedwithcontrol,
Twist,orZeb1siRNA,andsubsequentlytreatedwithvaryingconcentrationsofDoxfor48h.ThedottedlinesrepresenttheIC50values.Errorbarsdenote±S.E.M.*Po0.05;
**Po0.01. (e) Graph represents percentage cell invasion through Matrigel in Boyden chamber assay for MDAMB231 cells transfected with control or Twist siRNA, and
subsequently treated with Dox for 72h, n¼3. Error bars denote ±S.E.M. *Po0.05; ***Po0.001
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Cell Death and Diseaseissues, inhibitors of ABC transporters have proved to be
largely disappointing in clinical trials.
5 One possible reason
for this could be that most therapies till date have attempted
to target only a small subset of ABC transporters, namely
ABCB1, ABCC1, or ABCG2,
1,5,20 whereas recent studies
have demonstrated the involvement of as many as 16 ABC
transporters in cancer drug resistance.
5 Consistent with this,
our study reveals the existence of a large heterogeneity in
the expression of several of these transporters across
established breast cancer cell lines and primary tumor-
derived cells. Also, in response to chemotherapeutic drugs,
several breast cancer cells showed an increased expression
of a large number of ABC transporters simultaneously.
Furthermore, different cancer cell lines and primary samples
responded differently to the same drug by upregulating
diverse types of ABC transporters. As ABC transporters have
broad substrate recognition and redundancy in function, our
results suggest that future therapies should be designed
targeting several of these 16 ABC transporters as an
armamentarium of ‘MDR’ proteins.
EMT factors: link between invasion and drug
resistance. EMT is an evolutionarily conserved mecha-
nism characterized by the attainment of a mesenchymal
morphology, invasiveness, and changes in the expression of
epithelial and mesenchymal genes.
8 Cells undergoing EMT
become more migratory and invasive,
8 and invasive cancers
are known to be more drug resistant.
14,21 Furthermore,
the mesenchymal-like cells within a cancer have been shown
to be more drug resistant than the epithelial-like cells.
21 On
the other hand, drug-resistant cancer cells derived by
long-term exposure to drugs have been shown to acquire
mesenchymal morphology, increased migratory and invasive
potential, and an increased expression of EMT-regulating
transcription factors.
22–25 Our data revealed that even an
1-week treatment of invasive cancer cells sufﬁces to increase
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Figure 6 EMT-inducing transcription factors regulate ABC transporter expression. (a) Graph represents luciferase assay undertaken in MCF7 cells to assess the ABCC5
promoter activity (ABCC5-Luc; ﬁreﬂy luciferase) on co-transfection with pRL-TK (Renilla luciferase) and pBp-empty vector/Snail/mTwist/FOXC2. After 48h culture, ﬁreﬂy
luciferase activity was measured and normalized to Renilla luciferase activity and depicted as relative luciferase units (RLU), n¼3. Error bars denote ±S.E.M. *Po0.05;
**Po0.01. (b) Schematic of E-box elements in 2.2kb long promoter regions of ABCC4 and ABCC5 genes. (c) Gel picture represents PCR carried out on ChIP undertaken in
MCF7 cells transiently overexpressing Flag-Twist using anti-Flag Ab. PCR was carried out with the eluted DNA fragments using primers depicted in (b). No antibody (No Ab)
served as a negative control and rabbit IgG (Rab IgG) served as an isotype control. Control primers were designed B700bp upstream of E-box elements in the ABCC5
promoter and served as a speciﬁcity control
Table 1 ABC transporter promoters possess binding sites for EMT transcrip-
tion factors
Binding sites for EMT-inducing
transcription factors
ABC genes E-Box Twist FKHD E12 E47
ABCA2 15 9 2 2 3
ABCA3 16 3 6 2 2
ABCB1 31 2 2 0 1
ABCB4 667 2 3
ABCB5 14 1 3 0 3
ABCB11 14 1 2 0 2
ABCC1 21 11 21 6
ABCC2 13 1 3 0 1
ABCC3 442 1 2
ABCC4 11 3 3 0 1
ABCC5 629 0 2
ABCC6 42 1 1 1 0
ABCC10 32 1 4 0 1
ABCC11 08 2 3 1 2
ABCC12 359 2 1
ABCG2 61 1 2 1 1
Bioinformatic analysis (using the MatInspector software) of promoters of
ABC transporters for the presence of binding sites for EMT-inducing
transcription factors.
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Cell Death and Diseasetheir expression of EMT markers. Furthermore, induction
of EMT in immortalized/non-invasive cells led to increased
expression of ABC transporters and drug resistance,
whereas a reversal of EMT in invasive cells led to a
concomitant decrease in ABC transporter expression and
chemoresistance, thus establishing a strong link between
EMT and ABC transporter expression. Similar to our ﬁndings,
a recent study has reported that Dox treatment of cancer
cells enhances their invasion and drug-resistant phenotype
selectively in cells undergoing EMT.
26 We additionally
demonstrate that several ABC transporters contain binding
sites for EMT regulators like Twist, Snail, Slug, FOXC2, and
E12/E47, and at least three of these factors, Snail, Twist,
and FOXC2, can modulate the promoter activity of ABC
transporters. A ChIP experiment further conﬁrmed the role of
Twist in upregulating the expression of ABCC4 and ABCC5
transporters by directly binding to their promoters. Thus, our
data demonstrate for the ﬁrst time that the very transcription
factors that lead to cancer invasiveness by triggering EMT
directly modulate the expression of ABC family of drug
transporters, thereby contributing to chemoresistance.
EMT, cancer stem cells, and drug resistance. Although
our data provide a mechanistic link between EMT and drug
resistance, the question of how exposure to drugs induces
EMT remains unclear. One possibility is that the drugs
inﬂuence signal-transduction pathways upstream of EMT.
Indeed activation of TGFb signaling, a potent inducer of
EMT, in the presence of chemotherapeutic drugs has
recently been reported.
27 An alternate hypothesis, and an
Heterogeneous cancer
Epithelial-like cell
Mesenchymal-like cells
Express basal ABC transporters
Majority of epithelial-like cells die
Mesenchymal-like cells survive
expression of several ABC  
transporters
Acquisition of MDR 
Aggressive cancer stem-like cells
expression of EMT markers
mesenchymal morphology
migratory potential
invasive potential
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Drug efflux 
Chemotherapeutic drug treatment
EMT factors upregulate ABC transporters 
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Promoter regions of ABC transporters
mRNA transcripts of ABC transporters
EMT inducing transcription factors
Figure 7 A schematic representation of the effect of chemotherapy on invasive cancer cells. Chemotherapeutic treatment of a heterogeneous population of cancer cells
kills majority of the epithelial-like cells, whereas the mesenchymal-like cells survive owing to a basal expression of ABC transporters. Drug-induced activation of self-renewal
pathways(suchasTGFb)causesanincreaseintheexpressionofEMTtranscriptionfactors,mesenchymalmorphology,migratory,andinvasivepotentialofthesurvivingcells.
These EMT factors can then upregulate the expression of a large number of ABC transporters simultaneously, resulting in the generation of cancer stem-like cells that are
multidrug resistant
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Cell Death and Diseaseemerging theme in cancer biology, is that the drugs kill most
of the cells in the population leaving behind a small subset of
cells, called the cancer stem cells (CSCs), characterized
by their mesenchymal phenotype and increased expression
of ABC transporters and stemness markers.
9,21,28,29
Consistent with this, our data revealed that drug-treated
cells appeared more mesenchymal at the end of a week, and
revealed enhanced expression of stemness markers that are
currently being investigated. Furthermore, several signal-
transduction pathways involved in the regulation of stem cell
self-renewal (such as Notch, Wnt, and TGFb) have also been
associated with EMT and chemoresistance.
27,30,31
More recently, EMT markers and mesenchymal phenotype
have also been correlated with stemness.
32,33 Based on all
this, and in light of our observation that the previous presence
of an EMT machinery within a cell is a prerequisite
for upregulating their ABC transporters in response to drugs,
we suggest the following model: when a heterogeneous
population of cancer cells is treated with chemotherapeutic
drugs, the majority of the epithelial-like cells die. The
mesenchymal-like cells survive owing to a basal expression of
ABC transporters. Drug-induced activation of self-renewal
pathways within these cells causes further increase in the
expression of EMT factors, which in turn upregulate the
expression of a large number of ABC transporters simulta-
neously, resulting in the generation of multidrug-resistant,
cancer stem-like cells (Figure 7). This model also explains why
cancers that tend to initially respond to chemotherapy show a
much aggressive and multidrug-resistant phenotype on relapse.
Role of ABC transporters in migration and
invasion. Although on the one hand ABC transporters
appear to help cancer cells in evading chemotherapy,
these transporters may additionally have a direct role in
cancer cell migration and invasion during tumor progression.
In support of this, recent experiments have demonstrated
that dendritic cells lacking speciﬁc ABC transporters fail to
migrate to lymph nodes.
34 In addition, an elegant study in
Drosophila demonstrated that ABC transporters are essential
for controlling the export of a germ cell attractant during
directional cell migration during embryonic development.
35
Hence, increased expression of ABC transporters by
migratory cancer cells may additionally confer survival
advantage against harmful chemicals encountered in the
transiting microenvironments, and also regulate selective
export of signaling molecules that may aid their directional
migration. Thus, EMT-mediated upregulation of ABC trans-
porters could be an evolutionarily conserved mechanism,
which the cancer cells have exploited for their beneﬁt.
Taken together, our study revealed that in addition
to invasion, EMT inducers can promote drug resistance by
upregulating ABC transporters, which efﬂux chemotherapeu-
tic drugs. Our data provide novel insights into the molecular
mechanism behind the long-term association between cancer
invasivenessanddrugresistance,andsuggeststhattargeting
regulators of EMT may simultaneously tackle the intertwined
phenomena of metastasis, drug resistance, and CSCs, and
prevent cancer relapse. Thus, EMT regulators like Twist,
Snail, or FOXC2 transcription factors, self-renewal pathways
like TGFb, Wnt, and Notch that are known to induce EMT,
or microRNAs like miR200, miR155 involved with EMT
21 may
prove to be opportune therapeutic targets.
Materials and Methods
Cellcultureandreagents. Breastepithelial celllinesHBL100,T47D,MCF7,
MDAMB453, MDAMB435, MDAMB231, and BT549 (from ATCC) were cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) (Sigma-Aldrich, St. Louis, MO, USA)
supplemented with 10% fetal bovine serum (FBS), penicillin (1kU/ml), and
streptomycin (0.1mg/ml). HMLE was cultured as described previously
15 in DMEM-
F12 media containing 10ng/ml hEGF, 0.5mg/ml hydrocortisone, and 10mg/ml
insulin (Sigma-Aldrich). MCF10A cells were grown in DMEM-F12 supplemented
with 10% FBS, epidermal growth factor (20ng/ml), hydrocortisone (0.5mg/ml), and
insulin(10mg/ml).Theprimarybreastnormalandcancertissueswereprocessedas
described earlier.
36 After digestion and trypsinization, single cells were seeded in
attachment cultures for 1 week for drug treatment. Dox hydrochloride solution and
mitoxantrone were obtained from Sigma-Aldrich.
Primary samples. Normal, DCIS, and IDC primary tissue (untreated and
post-chemotherapy treated) samples were obtained from Kidwai Memorial Institute
of Oncology (KMIO), Bangalore, as per the Institutional Review Board and in
compliance with the ethical guidelines of KMIO and IISc.
Time-course drug assays. To determine the duration of drug treatment,
a time-course experiment was undertaken in MDAMB435 and MDAMB231 cells.
A total of 2 10
5 cells each were seeded in ﬁve 60mm dishes. After 24h of
seeding,oneplatewasharvestedasa0hminusDoxcontrol.Toalltheotherplates,
Dox was added to a ﬁnal concentration of 0.2mM. The media were changed every
third day and fresh drug was added. The plates were harvested in TRI reagent at
respective time points of 24, 48, and 72h and 1 week for subsequent RT-PCR-
based analysis (Supplementary Figure S6).
MTT assay. MTT assay was performed in triplicates in 96-well microtiter plates
(Greiner Bio-One, Frickenhausen, Germany). At 24h after seeding, speciﬁc
concentrations of Dox or mitoxantrone was added to independent wells and the
plates were incubated for another 48h in the incubator. MTT (5mg/ml) reagent
(Sigma-Aldrich)wasaddedtoeachwellandtheplatewasincubatedfor4huntilthe
formation of formazan crystals. After dissolving the crystals in DMSO, the plate was
read in ELISA reader at 540nm. Cell viability was expressed as the percentage of
the absorbance of drug-treated cells, relative to that of the untreated controls
(Supplementary Table S2).
RNA extraction and RT-PCR. Total RNA was isolated using the guanidine
isothiocyanate and phenol/chloroform method from TRI reagent (Sigma-Aldrich)
harvested cells. RT of mRNA was carried out using Gene-Amp RNA PCR cDNA
synthesis kit (Applied Biosystems, Carlsbad, CA, USA) according to the
manufacturer’s instructions. Speciﬁc primers used in the study were designed
using the Primer 3.0 software and sequences are mentioned in Supplementary
Table S3. Either b2-microglobulin, b-actin, or HPRT were used as normalizing
controls as mentioned in the ﬁgures.
Wound healing assay. Equal numbers of live cells were seeded in two
60mm dishes (Greiner Bio-One). Dox treatment was carried out for 72h when cells
were 90% conﬂuent. Cells were treated with 10mg/ml of mitomycin C (Calbiochem,
Gibbstown, NJ, USA) for 2h to arrest proliferation. Two wounds were made using a
P-200 pipette tip. Microphotographs were taken at 0 and 24h. The distance
migrated was quantiﬁed using the ProgRes capture software.
Matrigel invasion assay. In vitro tumor cell invasion assay was performed
using the BD BioCoat Matrigel Invasion Chambers as per the manufacturer’s
instructions. MDAMB231 cells were grown in the absence or presence of Dox for
72h at which timetheywere trypsinizedand50000 totallive cellswere usedfor the
experiment. At 24h after invasion, total cells were counted and plotted as invasion
index or % cell invasion.
EMT induction. The MCF7 cells were transiently transfected with pBp-empty
vector, pBp-Snail, pBp-mTwist, or pBp-FOXC2 expression constructs
(using Lipofectamine 2000; Invitrogen, Carlsbad, CA, USA) and subsequently
harvested at 48h post-transfection for further experimentation.
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Cell Death and DiseaseHMLE cells overexpressing Twist (HMLE-Twist) were generated by retroviral
transduction. Retroviruses were produced by transient transfection of 293T cells
with retroviral vectors (pBp-Snail, pBp-mTwist, or pBp-FOXC2) and packaging
plasmids (encoding pCMV-VSV-G and pUMVC3-gag-pol) using Fugene 6
(Roche Molecular Biochemicals, Mannheim, Germany). HMLE cells growing in a
60mmdishwereinfectedat40%conﬂuencywithviralsupernatantsalongwith8mg/
ml protamine sulfate and 10mM HEPES (4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid) for 6h, following which the viral particles were removed and fresh
media were added. After 48h of infection, drug selection with 0.5mg/ml of
puromycin was initiated. Clones of cells that emerged in the 60mm dish following
drug selection all showed similar morphological changes (mesenchymal
appearance). These clones were pooled and the experiments were performed in
the polyclonal population.
RNAi experiments. MDAMB231 cells were seeded in 60mm dishes and at
40% conﬂuency transfected with ON-TARGET plus SMART pool of non-targeting
control siRNA, Twist siRNA, or Zeb1 siRNA (Dharmacon, Lafayette, CO, USA)
using oligofectamine (Invitrogen) as per the manufacturer’s instructions in Opti-
MEM media. After 24h of transfection, Dox was added for another 72h following
whichcellsweretakenforeitherRT-PCR-basedanalysisorMatrigelinvasionassay.
ForDoxchemosensitivityexperiments,MDAMB231cellswereseededin96-well
microplates. After 24h, cells were transfected with non-targeting control siRNA,
TwistsiRNA,orZeb1siRNA.Afteranother24h,speciﬁcconcentrationsofDoxwere
added and the plates incubated for 48h at which time MTT reagent was added and
reading taken as described above.
Promoter analysis. The 2.2kb (2000bp upstream and 200bp downstream
of TSS) of promoter sequences were obtained using the DBTSS software and
promoter analysis was carried out using the MatInspector software, which identiﬁes
all potential binding sites for transcription factors.
Luciferase reporter assay. A total of 2 10
5 MCF7 cells were plated in
12-well plates(Greiner Bio-One). Cells were co-transfected with 800ng of pGL4.11b-
ABCC5 promoter-luciferase plasmid
37 and 800ng of pBp-empty vector, pBp-Snail,
pBp-mTwist, or pBp-FOXC2 in triplicates. To normalize transfection efﬁciency, cells
were also co-transfected with 50ng of the pRL-TK (Renilla luciferase). At 48h after
transfection, luciferase activity was measured using the Dual-Luciferase Assay kit
(Promega, Madison, WI, USA) in a scintillation counter for 10s. Fireﬂy luciferase
activity was expressed as relative light units compared with Renilla luciferase activity.
ChIP assay. ChIP assay was carried out essentially as per the standard
protocols.
38 In brief, MCF7 cells transfected with pCNDA3-Flag-Twist were
harvested after 72h, crosslinked with 1% formaldehyde for 10min at room
temperature, and then sonicated to obtain chromatin fragments ranging between
300 and 700bp. After pre-clearing with blocked protein-A beads (Bangalore Genei,
Bangalore, India), the soluble chromatin was equally divided and
immunoprecipitated with either rabbit anti-Flag antibody (Cell Signaling
Technology, Beverly, MA, USA) or a rabbit anti-IgG antibody (isotype control)
(Bangalore Genei) by incubation at 41C overnight. ‘No antibody’ control was also
incubated at 41C. Following washes, the antibody–protein–DNA complex was
eluted from the beads, followed by reverse crosslinking at 651C with 200mM NaCl.
After RNase (Sigma-Aldrich) and proteinase K (Sigma-Aldrich) treatment, the DNA
was puriﬁed by phenol–chloroform extraction. Equal amount of DNA was subjected
to PCR with primers speciﬁc for E-box sites within the ABCC4 and ABCC5
promoters. The sequences of the PCR primers used are mentioned in
Supplementary Table S4.
Statistical analysis. All statistical analysis was performed using the
GraphPad Prism 5.0 software. All data are presented as mean±S.E.M. P-values
o0.05 were considered to be statistically signiﬁcant. Ratio t-test was performed for
statistical analysis. All experiments were repeated thrice, unless otherwise stated.
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